Keywords: Janssen, Johnson & Johnson, Canagliflozin, Type 2 diabetes, Ferrer, Egrifta, AIDS/HIV, EMA

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

Article | 27 June 2012

Print This

US health care giant Johnson & Johnson’s (NYSE: JNJ) European subsidiary Janssen-Cilag International NV (Janssen) has submitted a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in